Study of a Booster Dose of Meningococcal Diphtheria Toxoid Conjugate Vaccine in Adolescents
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00777790 |
Recruitment Status :
Completed
First Posted : October 22, 2008
Results First Posted : March 19, 2009
Last Update Posted : February 14, 2014
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
This study was designed to evaluate the antibody response to a Menactra® booster dose in participants who previously received one dose of Menactra® or Menomune® as adolescents 3 years earlier in Study MTA02.
Primary Objective:
To evaluate the antibody responses to a booster dose of a tetravalent meningococcal diphtheria toxoid conjugate vaccine (Menactra®) in participants who had previously received Menactra® or Menomune® as adolescents in the MTA02 Study and antibody responses to a dose of Menactra® in naive adolescents.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Meningitis Meningococcemia | Biological: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 241 participants |
Allocation: | Non-Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Prevention |
Official Title: | Antibody Responses to a Booster Dose of an Experimental Tetravalent (A, C, Y, and W-135) Meningococcal Diphtheria Toxoid Conjugate Vaccine, Menactra® in Adolescents Who Previously Received Menomune® or Menactra® |
Study Start Date : | February 2004 |
Actual Primary Completion Date : | April 2004 |
Actual Study Completion Date : | April 2005 |

Arm | Intervention/treatment |
---|---|
Experimental: Menactra® Group
Received Menactra® vaccine in Study MTA02
|
Biological: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate
0.5 mL, Intramuscular
Other Name: Menactra® |
Experimental: Menomune® Group
Received Menomune® vaccine in Study MTA02
|
Biological: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate
0.5 mL, Intramuscular
Other Name: Menactra® |
Experimental: Control Group
Meningococcal vaccine-naïve Control Group.
|
Biological: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate
0.5 mL, Intramuscular
Other Name: Mneactra® |
- Geometric Mean Titers (GMTs) of Serum Bactericidal Activity for Each of the 4 Vaccine Serogroups. [ Time Frame: Day 0 and 8 and 28 days post-vaccination ]Geometric mean titers and their 95% confidence interval of serum bactericidal activity for the 4 vaccine serogroups before vaccination, at 8 days post- and 28 days post-booster dose of Menactra vaccine or a primary dose of Menactra vaccine in the meningococcal vaccine-naïve Control group.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 13 Years to 21 Years (Child, Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria :
- Participant is healthy, as determined by medical history and physical examination.
- Participant is at least 13 years of age but not yet 22 years of age at time of enrollment.
- For the Menactra® and Menomune® groups, participant received one dose of Menactra® or Menomune® in MTA02 trial and completed trial (2 blood samples, contacted for Month 6 safety follow up).
- For the Control group, participant has no previous history of any meningococcal vaccination.
- If < 18 years of age, participant has signed Institutional Review Board (IRB) approved informed assent form and his/her parent/legal guardian has signed an IRB-approved informed consent form.
- If ≥ 18 years of age, participant has signed an IRB-approved informed consent form.
- Able to provide vaccination log.
Exclusion Criteria :
- Serious chronic disease (i.e., cardiac, renal, neurologic, metabolic, rheumatologic, psychiatric etc).
- Known or suspected impairment of immunologic function.
- Acute medical illness with or without fever within the last 72 hours or an oral temperature ≥ 100.4ºF (≥ 38.0ºC) at the time of inclusion.
- For the Menactra® and Menomune® groups, history of documented invasive meningococcal disease or previous meningococcal vaccination with the exception of meningococcal vaccination given as part of MTA02 trial.
- For the Control group, history of documented invasive meningococcal disease or previous meningococcal vaccination.
- Administration of immune globulin, other blood products within the last three months, injected or oral corticosteroids or other immunomodulatory therapy within six weeks of the study vaccine. Individuals on a tapering dose schedule of oral steroids lasting < 7 days may be included in the trial as long as they have not received more than one course within the last two weeks prior to enrollment.
- Antibiotic therapy within the 72 hours prior to vaccination or antibiotic therapy within the 72 hours prior to having any blood sample drawn.
- Received any vaccine in the 14-day period prior to study vaccination, or scheduled to receive any vaccination during the 14-day period after study vaccination.
- Suspected or known hypersensitivity to any of the vaccine components.
- Unavailable for the entire study period or unable to attend the scheduled visits or to comply with the study procedures.
- In females, a positive or equivocal urine pregnancy test at the time of vaccination.
- Enrolled in another clinical trial.
- Any condition, which, in the opinion of the investigator, would pose a health risk to the participant, or interfere with the evaluation of the vaccine.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00777790
United States, Georgia | |
Atlanta, Georgia, United States, 30322 | |
Marietta, Georgia, United States, 30062 | |
United States, Massachusetts | |
Woburn, Massachusetts, United States, 01801 | |
United States, New York | |
Albany, New York, United States, 12208 | |
United States, Ohio | |
Akron, Ohio, United States, 44308 | |
Columbus, Ohio, United States, 43205 | |
United States, Pennsylvania | |
Sellersville, Pennsylvania, United States, 18960 | |
United States, Tennessee | |
Kingsport, Tennessee, United States, 37660 | |
United States, Virginia | |
Norfolk, Virginia, United States, 23501 |
Study Director: | Medical Monitor | Sanofi Pasteur Inc. |
Publications of Results:
Responsible Party: | Sanofi Pasteur, a Sanofi Company |
ClinicalTrials.gov Identifier: | NCT00777790 |
Other Study ID Numbers: |
MTA19 |
First Posted: | October 22, 2008 Key Record Dates |
Results First Posted: | March 19, 2009 |
Last Update Posted: | February 14, 2014 |
Last Verified: | January 2014 |
Meningitis Meningococcemia Neisseria meningitidis |
Diphtheria Meningitis Central Nervous System Diseases Nervous System Diseases Corynebacterium Infections |
Actinomycetales Infections Gram-Positive Bacterial Infections Bacterial Infections Bacterial Infections and Mycoses Infections |